AstraZeneca PLC (STO:AZN)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 2.05T |
| Revenue (ttm) | 551.90B |
| Net Income (ttm) | 78.01B |
| Shares Out | n/a |
| EPS (ttm) | 49.88 |
| PE Ratio | 26.28 |
| Forward PE | n/a |
| Dividend | 33.75 (2.58%) |
| Ex-Dividend Date | Feb 20, 2025 |
| Volume | 441,927 |
| Average Volume | 406,107 |
| Open | 1,311.00 |
| Previous Close | 1,320.00 |
| Day's Range | 1,306.50 - 1,331.50 |
| 52-Week Range | 1,226.00 - 1,799.00 |
| Beta | 0.18 |
| RSI | 41.16 |
| Earnings Date | Apr 29, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
AstraZeneca's bladder cancer treatment shows positive results in trial
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca's IMFINZI® (durvalumab) plus standard-of-care BCG inductio...
AstraZeneca, Daiichi post late-stage trial win for Enhertu in early-stage breast cancer
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11
AstraZeneca and Daiichi Sankyo's ENHERTU followed by THP showed an improved safety profile vs. standard of care First Phase III trial to demonstrate benefit of ENHERTU in early breast cancer Positive ...
Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model
Tempus AI Inc. (NASDAQ: TEM) during the first quarter secured a multi-million dollar deal to build “the world’s largest foundation model for oncology.” What Happened: During its first-quarter earning...
ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial
Daiichi Sankyo and AstraZeneca's ENHERTU followed by THP showed an improved safety profile versus standard of care First phase 3 trial to demonstrate benefit of ENHERTU in early breast cancer Results ...
Tempus AI raises revenue guidance to $1.25B for 2025, supported by new $200M AstraZeneca deal
AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma
AstraZeneca's Breztri met primary goals in ... Full story available on Benzinga.com
AstraZeneca succeeds in late-stage trials for asthma therapy
Alembic Pharma gets USFDA final nod for Ticagrelor 90 mg, tentative approval for 60 mg
Alembic Pharmaceuticals Limited announced on May 2, 2025, that it has received final approval from the US Food and Drug Administration (USFDA) for its Ticagrelor Tablets, 90 mg, and tentative approval...
AstraZeneca's Breztri meets main goals of late-stage asthma trials
Anglo-Swedish drugmaker AstraZeneca on Friday said its inhaler therapy Breztri Aerosphere met all the main goals of two late-stage trials in patients with uncontrolled asthma.
Step up now or lose jobs to US, AstraZeneca boss Pascal Soriot warns European pharma firms
Pascal Soriot (pictured) said innovation in pharma 'has mostly been funded by the US' as he doubled down on plans to grow the business in America.
What Does the Market Think About AstraZeneca?
AstraZeneca's (NYSE: AZN) short percent of float has fallen 41.18% since its last report. The company recently reported that it has 6.33 million shares sold short , which is 0.2% of all regular share...
AstraZeneca has built resilient supply chains in U.S., China: CEO
AstraZeneca CEO Pascal Soriot discusses earnings, the potential trade tariff impact on the business and the outlook for the firm's key markets.
Pharma firms maastraz
Jimmy Muchechetere, senior equity analyst at Investec, weighs in on the prospect of pharmaceutical tariffs and recent U.S. investment commitments from the sector.
AstraZeneca PLC (AZN) Q1 2025 Earnings Conference Call Transcript
AstraZeneca PLC (NASDAQ:AZN) Q1 2025 Earnings Conference Call April 29, 2025 6:45 AM ETCompany ParticipantsAndy Barnett - Head of IRPascal Soriot -...
AstraZeneca CEO talks tariffs, first quarter earnings
AstraZeneca (AZN) reported mixed first quarter earnings results, missing on revenue estimates but beating on earnings per share (EPS). The company also reaffirmed its 2025 outlook and has highlighted ...
AstraZeneca discontinues Truqap trial in castration-resistant prostate cancer
AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty
AstraZeneca Plc (NASDAQ: AZN) on Tuesday reported first-quarter 2025 sales of $13.59 billion, up 7% year over year (+10% at constant currency), slightly missing the consensus of $13.71 billion , driv...
AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty
AstraZeneca Plc AZN on Tuesday reported first-quarter 2025 sales of $13.59 billion, up 7% year over year (+10% at constant currency), slightly missing the consensus of $13.71 billion, driven by double...
AstraZeneca Beat Earnings Views, But Sales Come In Light As Cancer Study Flops
AstraZeneca stock was little moved Tuesday on a mixed earnings report and after the drug giant scrapped a failed cancer study.
AstraZeneca gets EU backing for lymphocytic leukemia treatment
EMA panel backs AstraZeneca's Calquence combo for leukemia. Read more here.
Drugmaker AstraZeneca shifts more production to US amid Trump tariffs
UK and rest of Europe risk losing out to US and China unless they ramp up spending on new medicines, says CEO Pascal Soriot Business live – latest updates AstraZeneca said it was shifting the producti...
AstraZeneca CEO hopes U.S. will represent half of company’s global revenue by 2030—vows to invest and expand in nation despite tariff threat
AstraZeneca's first quarter profit has risen by over 30 percent to $2.92 billion. The pharmaceutical giant said it remains on track to achieve its total target of $80 billion in annual revenue by 2030...
AstraZeneca PLC 2025 Q1 - Results - Earnings Call Presentation
The following slide deck was published by AstraZeneca PLC in conjunction with their 2025 Q1 earnings call.